seRNA – enter the next level of mRNA technology

Specific
Universal
Revolutionary
Fast

Specific
Universal
Revolutionary
Fast

We are developing the first pro-drug platform on RNA level, targeting oncological, viral and genetic diseases

It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.

seRNAs are combining the best of 3 worlds

RNAi interference

for cell specific targeting

mRNA

for cell functionalization via expression of the effector molecule

Fusogenic Liposomes

for organ-specific pre-targeting and delivery

RNAi interference

for cell specific targeting

mRNA

for cell functionalization via expression of the effector molecule

Fusogenic Liposomes

for organ-specific pre-targeting and delivery

more about technology

Writing a new chapter in treating diseases

We want to deliver more specific and effective treatments in the following areas:

Oncology

With primary liver cancer (HCC) and Glioblastoma we are treating two diseases of highest medical need based on locally and systemically applied seRNAs. For glioblastoma, animal data have already proven extraordinary effectiveness and biocompatibility of seRNA-based treatments.

Viral diseases

Viral RNAs represent ideal targets for seRNA activation. Activation takes place only in diseased cells due to lack of seRNA activators in healthy cells. We primarily pursue approaches to remove virally infected cells without affecting surrounding tissue.

Genetic diseases

Despite modern developments in the field of CrispR-Cas gene scissors, the technique still cannot be effectively used for developing treatments for genetic diseases due to its non-specific functionality. By combining CrispR-Cas with our seRNA technique, we are pursuing the approach of cell type-specific mutation repair.

Our pipeline

Our commitment

We are committed to opening a new chapter in treating diseases & bringing seRNAs to patients. seRNAs are a specific, fast, universal and revolutionary new treatment modality. We are getting more excited by seRNAs every day and will not rest until we have developed seRNAs to their full potential.

Our News